{"id":76787,"date":"2026-08-27T14:21:14","date_gmt":"2026-08-27T06:21:14","guid":{"rendered":"https:\/\/flcube.com\/?p=76787"},"modified":"2026-08-27T14:21:15","modified_gmt":"2026-08-27T06:21:15","slug":"micots-first-in-class-trkb-agonist-mt200605-meets-primary-endpoint-in-phase-2-acute-ischemic-stroke-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=76787","title":{"rendered":"Micot&#8217;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shaanxi Micot Pharmaceutical Technology Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/2355:HKG\">HKG: 2355<\/a>) announced that the <strong>Phase 2 trial<\/strong> of its independently developed drug candidate <strong>MT200605<\/strong> for the treatment of <strong>acute ischemic stroke (AIS)<\/strong> has been completed, demonstrating <strong>significant and robust efficacy advantages<\/strong> with a <strong>favorable safety profile<\/strong>. The readout advances a first\u2011in\u2011class small\u2011molecule <strong>TrkB agonist<\/strong> with a differentiated neuroprotective mechanism in one of neurology&#8217;s largest unmet\u2011need indications.<\/p>\n\n\n\n<h2 id=\"h-study-result-snapshot\" class=\"wp-block-heading\">Study Result Snapshot<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Sponsor<\/td><td><strong>Shaanxi Micot Pharmaceutical Technology Co., Ltd.<\/strong> (HKG: 2355)<\/td><\/tr><tr><td>Asset<\/td><td><strong>MT200605<\/strong>, first\u2011in\u2011class small\u2011molecule TrkB agonist<\/td><\/tr><tr><td>Phase<\/td><td>Phase 2 (completed)<\/td><\/tr><tr><td>Indication<\/td><td><strong>Acute ischemic stroke (AIS)<\/strong><\/td><\/tr><tr><td>Primary Endpoint<\/td><td>Proportion of patients achieving mRS score \u22641 \u2014 <strong>met with statistical significance<\/strong><\/td><\/tr><tr><td>Safety<\/td><td>Favorable safety profile reported<\/td><\/tr><tr><td>Announcement Date<\/td><td>26 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> MT200605, a first\u2011in\u2011class small\u2011molecule TrkB agonist capable of crossing the <strong>blood\u2011brain barrier<\/strong><\/li>\n\n\n\n<li><strong>Target:<\/strong> The <strong>BDNF\/TrkB signaling axis<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong>\n<ul class=\"wp-block-list\">\n<li>Blocks the ischemic cascade following AIS to <strong>protect neural tissues<\/strong><\/li>\n\n\n\n<li>Promotes <strong>neuronal regeneration and remodeling<\/strong> to facilitate repair of neurological damage<\/li>\n\n\n\n<li>Relaxes vascular smooth muscle, potentially <strong>improving microcirculation in the ischemic penumbra<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> A neuroprotective\/regenerative approach distinct from thrombolytic and thrombectomy\u2011centric standards of care in AIS<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-phase-2-mt200605-trial-in-ais\" class=\"wp-block-heading\">Clinical Evidence \u2013 Phase 2 MT200605 Trial in AIS<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Design:<\/strong> Multi\u2011center, randomized, double\u2011blind, placebo\u2011controlled study evaluating efficacy, safety, and pharmacokinetics<\/li>\n\n\n\n<li><strong>Enrollment:<\/strong> 360 subjects randomized 1:1:1:1 to low\u2011dose (10 mg BID), medium\u2011dose (20 mg BID), high\u2011dose (40 mg BID), or placebo<\/li>\n\n\n\n<li><strong>Dosing:<\/strong> Intravenous infusion for 14 consecutive days<\/li>\n<\/ul>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>High\u2011Dose (40 mg BID)<\/th><th>Placebo<\/th><th>Relative Benefit<\/th><\/tr><\/thead><tbody><tr><td>Primary: mRS \u22641 proportion<\/td><td>Notably higher<\/td><td>Lower<\/td><td>Statistically significant difference \u2014 endpoint met<\/td><\/tr><tr><td>AKI incidence<\/td><td>&gt;80% lower than placebo<\/td><td>Reference<\/td><td>Dose\u2011dependent reduction<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The high\u2011dose group met the primary efficacy endpoint, with a significantly higher proportion of patients achieving a <strong>modified Rankin Scale (mRS) score of \u22641<\/strong> versus placebo. Beyond neurological recovery, MT200605 demonstrated the potential to reduce the incidence of <strong>acute kidney injury (AKI)<\/strong> in AIS patients in a dose\u2011dependent manner \u2014 the high\u2011dose group showing an AKI incidence more than <strong>80% lower<\/strong> than placebo \u2014 suggesting a clinically meaningful organ\u2011protective dimension to the drug&#8217;s activity.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Large Unmet Need:<\/strong> Acute ischemic stroke remains a leading cause of death and disability worldwide, with limited therapeutic options beyond early reperfusion \u2014 positioning neuroprotective agents like MT200605 as potentially transformative complements to existing care.<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class Validation:<\/strong> Meeting the primary endpoint with statistical significance and a favorable safety profile de\u2011risks the BDNF\/TrkB agonist approach in AIS and strengthens Micot&#8217;s pipeline credibility.<\/li>\n\n\n\n<li><strong>Dual Benefit Potential:<\/strong> The observed dose\u2011dependent AKI reduction could broaden MT200605&#8217;s clinical value proposition beyond functional recovery, an angle worth exploring in Phase 3 design.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Phase 3 trial design and dosing selection (with the 40 mg BID high dose as the apparent frontrunner), full data disclosure for peer review, and partnership\/regional licensing discussions as the asset advances toward registration.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2013 This brief is for informational purposes only and does not constitute investment or medical advice. Statements regarding clinical development, efficacy interpretation, and future approvals are forward\u2011looking and subject to risks and uncertainties; actual results may differ materially. Refer to official announcements from Shaanxi Micot Pharmaceutical Technology for authoritative details.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082602042_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026082602042_c.\"><\/object><a id=\"wp-block-file--media-3eb8b61a-8ee5-400e-b021-12156e33fead\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082602042_c.pdf\">2026082602042_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/2026082602042_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-3eb8b61a-8ee5-400e-b021-12156e33fead\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[17,4797,4205],"class_list":["post-76787","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-results","tag-hkg-2355","tag-micot"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Micot&#039;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of its independently developed drug candidate MT200605 for the treatment of acute ischemic stroke (AIS) has been completed, demonstrating significant and robust efficacy advantages with a favorable safety profile. The readout advances a first\u2011in\u2011class small\u2011molecule TrkB agonist with a differentiated neuroprotective mechanism in one of neurology&#039;s largest unmet\u2011need indications.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=76787\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Micot&#039;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial\" \/>\n<meta property=\"og:description\" content=\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of its independently developed drug candidate MT200605 for the treatment of acute ischemic stroke (AIS) has been completed, demonstrating significant and robust efficacy advantages with a favorable safety profile. The readout advances a first\u2011in\u2011class small\u2011molecule TrkB agonist with a differentiated neuroprotective mechanism in one of neurology&#039;s largest unmet\u2011need indications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=76787\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T06:21:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-27T06:21:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76787#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76787\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Micot&#8217;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial\",\"datePublished\":\"2026-08-27T06:21:14+00:00\",\"dateModified\":\"2026-08-27T06:21:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76787\"},\"wordCount\":549,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial results\",\"HKG: 2355\",\"Micot Pharmaceutical Technology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76787#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76787\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=76787\",\"name\":\"Micot's First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-27T06:21:14+00:00\",\"dateModified\":\"2026-08-27T06:21:15+00:00\",\"description\":\"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of its independently developed drug candidate MT200605 for the treatment of acute ischemic stroke (AIS) has been completed, demonstrating significant and robust efficacy advantages with a favorable safety profile. The readout advances a first\u2011in\u2011class small\u2011molecule TrkB agonist with a differentiated neuroprotective mechanism in one of neurology's largest unmet\u2011need indications.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76787#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=76787\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=76787#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Micot&#8217;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Micot's First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of its independently developed drug candidate MT200605 for the treatment of acute ischemic stroke (AIS) has been completed, demonstrating significant and robust efficacy advantages with a favorable safety profile. The readout advances a first\u2011in\u2011class small\u2011molecule TrkB agonist with a differentiated neuroprotective mechanism in one of neurology's largest unmet\u2011need indications.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=76787","og_locale":"en_US","og_type":"article","og_title":"Micot's First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial","og_description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of its independently developed drug candidate MT200605 for the treatment of acute ischemic stroke (AIS) has been completed, demonstrating significant and robust efficacy advantages with a favorable safety profile. The readout advances a first\u2011in\u2011class small\u2011molecule TrkB agonist with a differentiated neuroprotective mechanism in one of neurology's largest unmet\u2011need indications.","og_url":"https:\/\/flcube.com\/?p=76787","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-27T06:21:14+00:00","article_modified_time":"2026-08-27T06:21:15+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=76787#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=76787"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Micot&#8217;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial","datePublished":"2026-08-27T06:21:14+00:00","dateModified":"2026-08-27T06:21:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=76787"},"wordCount":549,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial results","HKG: 2355","Micot Pharmaceutical Technology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=76787#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=76787","url":"https:\/\/flcube.com\/?p=76787","name":"Micot's First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-27T06:21:14+00:00","dateModified":"2026-08-27T06:21:15+00:00","description":"Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced that the Phase 2 trial of its independently developed drug candidate MT200605 for the treatment of acute ischemic stroke (AIS) has been completed, demonstrating significant and robust efficacy advantages with a favorable safety profile. The readout advances a first\u2011in\u2011class small\u2011molecule TrkB agonist with a differentiated neuroprotective mechanism in one of neurology's largest unmet\u2011need indications.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=76787#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=76787"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=76787#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Micot&#8217;s First\u2011in\u2011Class TrkB Agonist MT200605 Meets Primary Endpoint in Phase 2 Acute Ischemic Stroke Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=76787"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76787\/revisions"}],"predecessor-version":[{"id":76789,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/76787\/revisions\/76789"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=76787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=76787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=76787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}